Brief: BCAL Diagnostics Says Entered An Agreement With Precion Inc
28/06/2022 02:28
June 28 (Reuters) - BCAL Diagnostics Ltd BDX.AX :
* ENTERED INTO AN AGREEMENT WITH PRECION INC
* AGREEMENT FOR DEVELOPMENT OF CO'S BLOOD BASED TEST TO
DETECT
BREAST CANCER
Source text for Eikon: ID:nASX9kctWd
Further company coverage: BDX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures